PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

24 Jan 2013 15:33

RNS Number : 3321W
Ark Therapeutics Group PLC
24 January 2013
 



 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

ARK THERAPEUTICS GROUP PLC

2 Reason for the notification (please tick the appropriate box or boxes):

 

An acquisition or disposal of voting rights

 x

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

3. Full name of person(s) subject to the notification obligation:

 

 Henderson Global Investors

4. Full name of shareholder(s) (if different from 3.):

 

5. Date of the transaction and date on which the threshold is crossed or reached:

 

 21 January 2013

6. Date on which issuer notified:

 

 23 January 2013

7. Threshold(s) that is/are crossed or reached:

 

 5%

8. Notified details:

A: Voting rights attached to shares

 

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights

Direct

Direct

Indirect

Direct

Indirect

 ORD GBP 0.01

 12,810,000

12,810,000

5,310,000

2.53%

 GB0034251727

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

Expirationdate

Exercise/ConversionPeriod

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

Exerciseprice

Expirationdate

Exercise/Conversionperiod

Number of votingrights instrumentrefers to

% of voting rights

 

Nominal

Delta

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 5,310,000

2.53%

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14. Contact name:

 Balenkosi Dungeni

15. Contact telephone number:

 020 7818 3747

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUSOVROAAAUAR
Date   Source Headline
6th Sep 20134:40 pmRNSSecond Price Monitoring Extn
6th Sep 20134:35 pmRNSPrice Monitoring Extension
6th Sep 201312:54 pmRNSHolding(s) in Company
4th Sep 20134:40 pmRNSSecond Price Monitoring Extn
4th Sep 20134:35 pmRNSPrice Monitoring Extension
2nd Sep 201312:00 pmRNSHolding(s) in Company
29th Aug 20134:41 pmRNSSecond Price Monitoring Extn
29th Aug 20134:35 pmRNSPrice Monitoring Extension
29th Aug 20139:00 amRNSHalf Yearly Report
16th Aug 20134:40 pmRNSSecond Price Monitoring Extn
16th Aug 20134:35 pmRNSPrice Monitoring Extension
15th Aug 20135:32 pmRNSHolding(s) in Company
14th Aug 20134:56 pmRNSHolding(s) in Company
30th Jul 20134:40 pmRNSSecond Price Monitoring Extn
30th Jul 20134:35 pmRNSPrice Monitoring Extension
23rd Jul 20133:44 pmRNSHolding(s) in Company
9th Jul 20132:00 pmRNSCompany Update
8th Jul 20134:40 pmRNSSecond Price Monitoring Extn
8th Jul 20134:35 pmRNSPrice Monitoring Extension
5th Jul 201310:48 amRNSHolding(s) in Company
5th Jul 20137:00 amRNSCompany Update
27th Jun 20134:40 pmRNSSecond Price Monitoring Extn
27th Jun 20134:35 pmRNSPrice Monitoring Extension
25th Jun 20132:05 pmRNSResults of Annual General Meeting
14th Jun 20134:40 pmRNSSecond Price Monitoring Extn
14th Jun 20134:35 pmRNSPrice Monitoring Extension
4th Jun 20132:48 pmRNSBlocklisting Six Monthly Return
24th May 20134:40 pmRNSSecond Price Monitoring Extn
24th May 20134:35 pmRNSPrice Monitoring Extension
17th May 20137:00 amRNSInterim Management Statement
16th May 20131:20 pmRNSHolding(s) in Company
8th May 20136:09 pmRNSHolding(s) in Company
8th May 20135:47 pmRNSHolding(s) in Company
2nd May 20131:45 pmRNSHolding(s) in Company
1st May 20134:35 pmRNSPrice Monitoring Extension
30th Apr 20137:00 amRNSFinal Results
26th Apr 20134:50 pmRNSHolding(s) in Company
24th Apr 20133:47 pmRNSHolding(s) in Company
26th Mar 20134:40 pmRNSSecond Price Monitoring Extn
26th Mar 20134:35 pmRNSPrice Monitoring Extension
22nd Mar 201311:50 amRNSHolding(s) in Company
20th Mar 20131:15 pmRNSHolding(s) in Company
19th Mar 201311:34 amRNSForm 8.3 - Ark Therapeutics
19th Mar 20139:47 amRNSHolding(s) in Company
18th Mar 20131:54 pmRNSForm 8.3 - Ark Therapeutics Group PLC
15th Mar 201312:01 pmRNSTermination of Offer Period and Rule 10.8 Waiver
7th Mar 20134:22 pmRNSForm 8.3 - [Ark Therapeutics Group]
6th Mar 20133:04 pmRNSForm 8.3 - [Ark Therapeutics Group]
6th Mar 201310:02 amRNSForm 8.3 - Ark Therapeutics Group Plc
1st Mar 201311:49 amRNSForm 8.3 - Ark Therapeutics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.